期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

托珠单抗在新冠肺炎的合理使用及药学监护 被引量：4

Rational use of tocilizumab in COVID-19 pneumonia and pharmaceutical care
下载PDF
导出
摘要 《新型冠状病毒肺炎诊疗方案(试行第七版)》新增托珠单抗的免疫治疗方案。本文对托珠单抗治疗新冠肺炎的合理使用及药学监护进行论述,以期为临床提供参考。 Tocilizumab was recommended in the"Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme( Trial version 7.0)".In this paper,the rational use of tocilizumab in the treatment of COVID-19 pneumonia and pharmaceutical care are discussed in order to provide a reference for clinical practice.
作者 梁虹艺 万宁 林伟斌 季波 LIANG Hongyi;WAN Ning;LIN Weibin;JI Bo(General Hospital of Southern Theatre Command,Guangzhou 510010,China;Army Supports Pharmacy Staff of Hubei Medical Team,Wuhan 430000,China)
机构地区 南部战区总医院 军队支援湖北医疗队
出处 《广东药科大学学报》 CAS 2020年第3期388-391,402,共5页 Journal of Guangdong Pharmaceutical University
关键词 托珠单抗 新冠肺炎 细胞因子风暴 药学监护 tocilizumab COVID-19 cytokine storm pharmaceutical care
分类号 R563.1401 [医药卫生—呼吸系统]
  • 相关文献

参考文献9

二级参考文献24

  • 1杨臻真.白介素-6受体抗体Tocilizumab[J].药学进展,2005,29(9):431-432. 被引量：1
  • 2Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther, 2012, 91: 607-620.
  • 3Horton SC, Walsh CA, Emery P. Established rheumatoid arthri- tis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol, 2011, 25: 509-521.
  • 4Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hobo- ken), 2012, 64: 625-639.
  • 5Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis, 2006, 65: 746-752.
  • 6Thalayasingam N, Isaaes JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol, 2011, 25: 549-567.
  • 7Moots RJ, Ostor AJ, Isaacs JD. Win treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remis- sion'? Expert Opin Investig Drugs, 2009, 18: 1687-1699.
  • 8Koike R, Harigai M, Atsumi T, et al. Japan College of Rheuma- tology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol, 2009, 19: 351-357.
  • 9Navarro-Mill6n I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent target- ing the interleukin-6 receptor. Clin Ther, 2012, 34: 788-802.
  • 10Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis, 2012, 71 Suppl 2: i2-45.

共引文献52

同被引文献50

引证文献4

二级引证文献8

广东药科大学学报
2020年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部